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Introduction 
 
  I come to you this morning not as an intellectual property lawyer but 
as a former general counsel of biotechnology and pharmaceutical related 
companies, as an attorney with significant exposure to intellectual property 
issues and as one who has seen first-hand the importance of intellectual 
property in shaping commercial strategies in biotechnology.  With that as a 
backdrop, I would like to thank you for allowing me the opportunity to share 
with you today thoughts that I have regarding patents and the impact of 
patent reform on biotechnology.  It has been said that the best way to predict 
the future is to invent it.  However, I believe that the best way to control the 
future is to patent it. 
                                                 
∗ Vincent J. Napoleon is Counsel at the global law firm of Pillsbury where he is a member of the life 
sciences, corporate and government contracts practice groups.  He received his J.D. from the University 
of Pittsburgh School of Law and his B.S. in Business Administration from Georgetown University. 
** I wish to thank Carl W. Battle, Chief Intellectual Property Counsel for Elan Pharmaceuticals, Inc, for his 
thoughtful comments and input as I developed my presentation. 
 
The existence of patents and patent law policy is, on one level, to 
protect patent holders and their discoveries while, on another level, it exists 
to foster innovation while facilitating and promoting the inventive process 
and commercialization.1  In addition, patents and patent law reform policy 
assist firms, small and large, in attracting venture capital by signaling that a 
firm possesses valuable knowledge capital.2  On a global basis, countries 
traditionally develop patent policies to complement industrialization and 
trade by encouraging invention and innovation.  We have seen this with the 
promulgation of the Patent Cooperation Treaty, the Convention on the Grant 
of European Patents, the Agreement on Trade Related Aspects of Intellectual 
Property Rights (commonly referred to as the “TRIPS Agreement” or 
“TRIPS”) and the further efforts by the World Intellectual Property 
Organization (WIPO) to examine the harmonization of domestic patent laws 
at the international level.3   
 While patents and the associated policies and reforms have impacted 
the direction of many technology driven industries, there is no one area 
greater than biotechnology where its influence is felt.  Although a relatively 
                                                 
1  See John M. Golden, Biotechnology, Technology, and Patentability: Natural Products and Invention in 
the American System, 50 EMORY L.J. 101 (2001). 
2  Stuart Minor Benjamin and Arti K. Rai, Who’s Afraid of the APA?  What the Patent System can Learn 
from Administrative Law, 95 GEO. L.J. 269, 275 (2007). 
3  See Jerome H. Reichman and Rochelle Cooper Dreyfuss, Harmonization Without Consensus: Critical 
Reflections on Drafting a Substantive Patent Law Treaty, 57 DUKE L.J. 85 (2007). 
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young and emerging sector of the global economy,4 biotechnology, along 
with its innovation and investment, depends on a reliable and strong 
intellectual property system generally and a robust global patent system 
specifically.  Patents enable biotechnology firms to increase their expected 
profits from investments in research and development while fostering 
innovation that would not occur but for the existence of the patent.5  Patents, 
moreover, promote the dissemination of scientific and technical information 
that would otherwise be unavailable but for the prospect of the patent.6  In 
short, as indicated by World Intellectual Property Organization, patents are a 
mechanism that encourages creative activity, industrialization, investment, 
and honest trade thereby, contributing more to our global safety and comfort, 
less poverty and more beauty in our lives.  The strength of a robust patent 
system and the protections accorded by such a system is rationalized by 
several goals.  They include, 1) incentivizing creativity; 2) rewarding 
creativity; 3) providing rights to patent owners for the fruit of their creative 
labor; 4) satisfying principles of moral and natural rights; 5) promoting 
public disclosure of new information; 6) facilitating transfer of innovation; 
                                                 
4  See INNOVATION IN GLOBAL INDUSTRIES: U.S. FIRMS COMPETING IN A NEW WORLD (Collected Studies) 
243 (2008). 
5  See Antitrust Modernization Commission: Hearing on Patent Law Reform, 109th Cong. 2 (2005) 
(statement of Susan. S. DeSanti, FTC Deputy General Counsel for Policy Studies.) 
6  Id. 
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7) facilitating investment in innovation; and 8) implementing industrial 
policy. 
 As a new entrant into the world economy, biotechnology and its 
associated patents and intellectual property are subject to pubic and political 
climate changes that may either adversely or positively impact 
biotechnology innovation.  Theses changes, for example, range from 
legislative reform to judicial decisions to challenges to the United States 
Patent Office rule-making authority and to the United States Trade 
Commission patent enforcement activities to the TRIPS implementation.  
All of these policy and reform activities have, as a result, added a level of 
uncertainty to patent procurement, enforcement and business decision 
making.  Clearly, the biotechnology industry, in its relative infancy, is 
confronted with challenges as it navigates through the myriad of patent 
related reforms and, in some cases, general public and political opposition to 
biotechnology patents.  To understand these challenges, it is important to 
understand the development of patent law and patent policy in addition to 
the global demand for biotechnology and the impact of changes on 
biotechnology investment and innovation.  
As we turn our attention to patent Law and Policy Development, we 
understand that the global demand for biotechnology and its resultant 
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products is significant.  This demand is driven by the needs of a growing and 
aging world population and by the innovation that emerges from patent laws 
and policies.7  To fully appreciate patent laws and policies, it is important to 
understand the historical context from which they have evolved.  Patent 
laws, for example, were first promulgated in Venice during the 15th century 
as part of a policy to improve a fledgling Venetian economy that was 
suffering as a result of a substantial war between Venice and Turkey.8  The 
impetus of Venetian patent law was the recognition that knowledge of a craft 
or a technology, such as the art of glassmaking, could have value apart from 
the products produced by such craft or technology.9  The stated 
governmental policy regarding patents encouraged inventions by making it 
unprofitable for infringers to copy inventions and “take the inventor’s honor 
away.”10  Granting inventors exclusive rights to their inventions, the 
Venetian patent law system influenced other countries to develop policies 
that would stimulate invention and innovation and the development of new 
industries through the issuance of patents.11   
                                                 
7 INNOVATION IN GLOBAL INDUSTRIES: U.S. FIRMS COMPETING IN A NEW WORLD (Collected Studies) 239 
(2008).  
8 See Srividhya Ragavan, Can’t We All Get Along? The Case for a Workable Patent Model, 35 ARIZ. ST. 
L.J. 117, 121 (2003). 
9 See Thomas M. Meshbesher, The Role of History in Comparative Patent Law, 78  J. PAT. & TRADEMARK 
OFF. SOC’Y 594, 605 (1996). 
10 Id. 
11 Id. 
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The Venetian law, which granted inventors exclusive rights for a 
limited time, influenced development of patent law and policy in other 
countries.12  France and the Netherlands in the sixteenth, seventeenth and 
eighteenth centuries developed policies that resulted in the grant of patents 
to individuals; thus, creating private rights as an incentive for encouraging 
individuals to create new inventions.13   
The British system of patent law, developed some 100 years after the 
Venetian system, developed in the form of the crown’s prerogative to issue 
letters patent bestowing privileges upon individuals in furtherance of royal 
policies.  This was the beginning of a deliberate and vigorous policy to 
expand British industry.14  These letters patent were issued to foreigners 
coming to England for the purpose of training British subjects in various 
trades.15  A tool of economic development,16 they were also granted to 
attract foreign industries into England enabling Britain to become 
economically self-sufficient.17  Clearly, the policy surrounding the 
development of patent laws in the United Kingdom was fueled by the need 
to stimulate domestic production and manufacturing.  However, as part of a 
                                                 
12 Ragavan, supra note 8, at 121. 
13 Meshbesher, supra note 9, at 607. 
14 Id. 
15  Ragavan, supra note 8, at 122. 
16 Paul E. Schaafsma, An Economic Overview of Patents, 79 J. PAT. & TRADEMARK OFF. SOC’Y 241, 242 
(1997). 
17 Ragavan, supra note 8, at 122. 
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reform that took place between the 1600s and 1800s there was a 
fundamental shift in British patent policy — a reform that went from 
viewing patents as a contract between the crown and the patentee to viewing 
patents as a social contract between the patentee and society.   In short, the 
British patents evolved from being a royal prerogative to a system based on 
and adjudicated by common law courts to a system that is rooted in statute 
representing a legal right obtained by an inventor for the exclusive control 
over his invention.18 
Unlike the British system of patent law which had its beginnings in 
royal prerogatives, the American patent law and policy is rooted in 
legislation and administrative procedure.19  Viewed as the most dynamic 
patent system in the world, modern patent law and policy in the United 
States has its genesis in early drafts of the United States Constitution where 
the U.S. Congress was authorized to create a national patent law resulting in 
the subsequent introduction of the Patents Act in 1790.20  This was a major 
reform in the history of patent law because it established important basic 
principles of patent law that serves as the bedrock of patent systems existing 
in other developed countries around the world.  These principles include the 
                                                 
18  Id. at 123 (referring to the Patents Acts of 1997). See also Adam Mossoff, Rethinking the Development 
of Patents: An Intellectual History, 1550-1800, 52 HASTINGS L. J. 1255, 1255 (2001). 
19 Meshbesher, supra note 9, at 609. 
20 Ragavan, supra note 8, at 123. 
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ability of any person to 1) petition certain governmental officials to obtain a 
patent for an invention or discovery; 2) deliver to governmental officials a 
specification in writing “containing a description” of the invention to be 
patented; 3) petition for a patent for a term not exceeding a specified number 
of years; 4) petition for a patent on an invention that is sufficiently useful 
and important; 5) be accorded an evidentiary presumption favoring the 
patentee; and 6) be charged a fixed fee for filing a patent application.21  
Indeed, it was the Patents Act of 1790 coupled with the changing economic 
environment over the next century that lead to further reform.     
Driven further by the economics of the time, the most significant of 
the patent law and policy reform that occurred subsequent to the Patents Act 
of 1790 was the promulgation of the Patent Act of 1952 (the “Patent Act”).  
This legislation, which represents the basic structure of the current U.S. 
patent law system, coupled with the subsequent passage of the Federal 
Courts Improvement Act22 enabled the United States to emerge as the 
forerunner in encouraging patents in areas like chemicals, business methods, 
software and biotechnology.  Development of patents in the emerging area 
of biotechnology became so vast in the U.S. that countries like Germany and 
                                                 
21 See Patent Act of 1790, ch. 7, 1 Stat. 109 (1790). See also Meshbesher, supra note 9, at 610.  
22 The Federal Court Improvement Act established The Court of Appeals for the Federal Circuit and vested 
in it jurisdiction to hear patent appeals. 35 U.S.C. § 141 (2006). 
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the United Kingdom began to follow suit in the trend to support 
biotechnology patent development.  Beginning with the Venetians, it has 
taken several centuries, influenced by the French, the British and the 
American patent systems, to develop a sustainable patent policy that has 
now made its way to influence the area of biotechnology. 
 Indeed, the United States and other developed countries have both 
strengthened the scope of patent laws while expanding the range of the 
subject matter covered.  The intellectual property system and more 
specifically the global patent regime as we currently know it has grown and 
changed over the centuries through legal reforms as well as through business 
and technical innovation.  Notwithstanding these gains in patent law 
development and reform, international protection of intellectual property, 
particularly patents, has been a global objective23 bringing us to a time 
where creativity and innovation impacts everyone, rich and poor, in every 
nation — both developed and developing — affecting each of us in 
important and complex ways.  More modern reform has begun to address 
these concerns through the enactment of the TRIPS Agreement.24   
                                                 
23 See Andrew Beckerman-Rodau, Patent Law – Balancing Profit Maximization and Public Access to 
Technology, 4 COLUM. SCI. & TECH. L. REV. 1, 2 (2002). 
24 Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15, 1994, 33 I.L.M. 1197 
(1994). See also Ragavan, supra note 8, at 117 and Id.  
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The TRIPS Agreement introduced intellectual property law into the 
international trading system for the first time, and remains the most 
comprehensive international agreement on intellectual property to date.  
TRIPS requires member countries to grant patents in all fields of technology, 
subject to the normal test of novelty, inventiveness and industrial 
applicability and without regard to the place of the invention.25  TRIPS also 
allows member countries to, among other things, enforce intellectual 
property rights through trade sanctions.26  The TRIPS Agreement specifies 
the subject matter to be protected, the minimum duration of protection as 
being twenty years, the rights to be conferred and permissible exceptions.27  
In as much as the TRIPS Agreement provides member states a 
comprehensive global patent regime, there are concerns, particularly those 
posited by developing countries, that economic conditions of their respective 
nations may preclude their embracing the Agreement.28  Notwithstanding 
the intent and benefits of TRIPS, developing countries are struggling to 
adjust to the heightened standards of intellectual property protection req
by TRIPS while also seeking to harmonize their domestic patent laws an
uired 
d 
                                                 
25 Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15, 1994, 33 I.L.M. 1197 
(1994). 
26 Id. 
27 Id. 
28 Reichman and Dreyfuss, supra note 3, at PINPOINT. 
 
 
10
policies at the international level.29  Some would argue that while the TRIPS 
Agreement elevated patent standards globally, developing countries are 
struggling to absorb the social costs inherent in complying with this 
regime.30  The British Government’s Department of International 
Development through its Commission on Intellectual Property Rights 
concluded that an expansion of intellectual property rights under TRIPS is 
unlikely to result in significant benefits for most developing countries.  
Should developing countries be coerced into accepting developed world 
practices in patenting, the likelihood of higher priced medicines and other 
biotechnology related products would be the outcome.31  Similarly, the 
African Group of countries in the World Trade Organization further 
expressed the concerns of developing countries on this point concluding that 
the expanded global patent regime outlined in the TRIPS Agreement has the 
propensity of yielding high priced patented drug treatments putting 
treatments for diseases like HIV/AIDS and other vitally-needed medicines 
out of the reach of those who need these treatments most.32  Those who 
argue against the TRIPS level of international patent reform, however, fail to 
                                                 
29 Id. 
30 Ragavan, supra note 8, at 118. See also Reichman and Dreyfuss, supra note 3, and Beckerman-Rodau, 
supra note 23. 
31 See Commission on Intellectual Property Rights, Integrating Intellectual Property Rights and 
Development Policy: Report of the Commission on Intellectual Property Rights (2002). 
32 See Cecilia Oh & Ruth Mayne, Please Join in the NGO Statement: ‘Patents and Medicines: The WTO 
Must Act Now!  (2001), http:/www.twnside.org.sg/title/joint4.htm. 
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understand that TRIPS and harmonization provide needed incentive for 
inventors to invest in innovative sectors like biotechnology, to make high 
technology products available to local industries, to provide patent and 
licensing arrangements while providing a platform for direct foreign 
investment.33 
From the early development of patent law and policy to the more 
modern day patent regimes to facilitate the growth of economies and the 
development of new technology sectors such as biotechnology, we as a 
world community, more than ever, possess the appropriate economic tools in 
patents to incentivize the inventive process and innovation.  In doing so, 
through the efforts and knowledge base of biotechnology firms, we position 
ourselves to develop and identify treatments for some of the world’s 
deadliest diseases — namely cancer, heart disease, Parkinson’s, 
Alzheimer’s, HIV/AIDS and others. 
Global Demand for Biotechnology 
 With patent law and policy development as a framework, let us turn 
our attention to biotechnology and the global demand.  Biotechnology is one 
of the most promising new high-tech phenomena advancing our global 
economy.  It is responsible for a new wave of DNA based therapeutic drugs 
                                                 
33 Reichman and Dreyfuss, supra note 3, at 94. 
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and diagnostics fueling the development of innovative products including 
genetically engineered forms of substances like insulin, human growth 
hormone and therapies like Enbrel for rheumatoid arthritis and Gleevec, a 
treatment for chronic myelogenous lukemia.34  It is also a complex, fast 
moving, highly entrepreneurial, science-driven discipline that continually 
calls for new and evolving approaches to solving some of the global health 
issues that affect each and every one of us around the world.  Relative to the 
size of other industries, the absolute size of the biotechnology industry is 
modest.  However, the engine of innovation for the drug development 
industry, biotechnology firms achieved record revenue in 2007 crossing the 
$80 billion threshold for the first time.35  Referring to the following chart, 
we see that year over year revenue has increased from $73 billion with an 
upward trend over the last three years.  As biotechnology companies seek to 
achieve competitive advantage through the exploitation of their intellectual 
property generally and their patents more specifically, managing these assets 
and responding to the influence of patent policy makers in this area has 
become a key issue for these companies.  The history of biotechnology 
patenting in the U.S. essentially arose out of the development of 
                                                 
34 See John A. Tessensolm, Publish and Not Perish: Japan’s Universities Designated to Enjoy Patent 
Novelty Grace Period Amidst Promethean Changes In Biotechnology & University Patenting, 8 ASIAN 
PACIFIC L. & POL’Y J. 292, 293 (2007) (referring to note 6). 
35 See ERNST & YOUNG, BEYOND BORDERS: GLOBAL BIOTECHNOLOGY REPORT 23 (2008). 
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methodologies in the 1970s and early 1980s that allowed for the cloning of 
human genes.  These genes produced large quantities of recombinant human 
protein therapeutics, which were the first important products of 
biotechnology.36  The formal recognition of biotechnology patents occurred 
during this period with the U.S. Supreme Court decision in a case in which a 
General Electric Company genetic engineer applied for a patent on a 
genetically engineered bacterium that could break down crude oil.37  The 
issuance of the patent was allowed on the basis that patent law, according to 
the Court, extends to living creatures as long as they are not naturally 
occurring but made by humans.38  As a result of the Supreme Court’s 
decision in this case and subsequent cases, legislative action and a resultant 
favorable patent climate for biotechnology innovation, the U.S. benefited 
from an environment that encouraged the commercialization of new 
biotechnology products.39  Indeed, the United States is the dominant country 
of origin for biotechnology innovations, even those innovations that may be 
patented in Europe.40  This view is further illustrated in the graphs in Figure 
                                                 
36 See Christopher M. Holman, The Impact of the Human Gene Patents on Innovation and Access: A Survey 
of Human Gene Patent Litigation, 76 UMKC L. REV. 295, 323 (2007). 
37 Diamond v. Chakrabarty, 447 U.S. 303, 305 (1980). 
38 MICHAEL R. TAYLOR AND JERRY CAYFORD, RESOURCES FOR THE FUTURE, AMERICAN PATENT POLICY, 
BIOTECHNOLOGY, AND AFRICAN AGRICULTURE: THE CASE FOR POLICY CHANGE 30 (2003).  
39 Raine Hermans et al., Biotechnology, in Innovation in Global Inudstries: U.S. Firms Competing in a New 
World 231, 259 (Jeffrey T. Macher & David C. Mowery eds., 2008). 
40 Id. at 256. 
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1, which highlight the number of biotechnology patents filed in the US 
Patent and Trademark Office and the European Patent Office by region of 
origin of the inventor.  In both instances we see that the United States has at 
least doubled the innovative capacity of Japan and the European Union.  
This gap is, in large part, the result of the large scale private and public 
biotechnology research funding in the United States relative to Japan and the 
European Union.41   
Notwithstanding the U.S. lead, attempts to close the gap between the 
United States and the European Union occurred through the European 
Union’s implementation of the Directive on Legal Protections of 
Biotechnologies.  The implementation of this Directive was a significant 
step by the European Union towards improving the patent climate for the 
biotechnology industry in Europe42 for the attraction and retention 
biotechnology innovation.  Such effort allows the EU to keep pace with U.S. 
biotechnology and the competition for research dollars while also creating a 
friendly environment for biotechnology research.43  In addition, research and 
development investment expenditures in the U.S. are an order of magnitude 
higher than any other individual country.  Similarly, venture capital 
                                                 
41 The National Institute of Health, for example, through its increases in funding, complements venture 
capital and private investment which is typical in biotechnology. 
42 See Robin Beck Skarstad, The European Union’s Self-Defeating Policy: Patent Harmonization and the 
Ban on Human Cloning, 20 U. PA. J. INT’L ECON. L. 353, 353-54 (1999). 
43 Id. at 355. 
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investment in the U.S. is greater than other countries signifying the United 
States’ continued dominance in the creation and evolution of biotechnology 
enterprises.44  Referring to Figure 2, if we view biotechnology as three 
classes — health-oriented biotechnology (Red), agriculture-focused 
biotechnology (Green) and industrial-related biotechnology (White) — we 
find that U.S. leadership in biotechnology is in patent classes that are more 
related to health-oriented biotech while the EU and Japan patenting activity 
is greater in the agriculture-focused and industrial related biotechnology 
areas.  The patterns shown in Figure 2 reflect the historical strength of the 
EU in the chemical industry and related industrial applications of 
biotechnology.  Similarly, the relative strength of Japanese inventors is 
apparent in areas such as waste disposal and the environment and chemicals. 
These patterns and figures suggest that the United States leadership in 
biotechnology is by no means monolithic.45  According to the World 
Intellectual Property Organization, in the last year, we have seen a plethora 
of patents filed under the Patent Cooperation Treaty, which serves as the 
cornerstone of the international patent system.46  Referring to Figures 3 and 
4, with the U.S., Japan and Germany leading in filings, a total record of 
                                                 
44 Hermans et al., supra note 39, at 253. 
45 Id. at 260. 
46 Press Release, World Intellectual Property Organization, Unprecedented Number of International Patent 
Filings in 2007 (Feb. 21, 2008), http://www.wipo.int/pressroom/en/articles/2008/article_0006.html. 
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156,000 applications was filed in 2007.  This represents a 4.7% rate of 
growth in filings over the previous year with the U.S. representing 34% of 
the total global patent filings in 2007.  The growth as reflected in the chart 
indicates shifting patterns of innovation around the world.  It also reflects the 
relative strength of patents, including those which are biotechnology related, 
as visualized from a three dimensional perspective and as depicted in Figure 
5. In this regard, consideration of patents is given in terms of 1) legal scope 
— considering the scope of exclusive rights in the covered subject matter;  
2) geographical range — considering validity of rights in various countries; 
and 3) duration — considering the length or duration of the rights derived 
from the patent.  Notwithstanding the growth rate in total patent filings, the 
gap in the global distribution of biotechnology patents and innovation 
between the United States and the rest of the world has remained relatively 
constant.47  To close this gap, it requires a greater diffusion of ideas which 
leads to newer ideas through the expansion of public domain knowledge on 
which others can build.  It is a cycle, as depicted in Figure 6 that results in 
the creation of new works from existing knowledge with sharing and 
establishing a new threshold for innovation.    
 
                                                 
47 Id. 
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Key Patent Activities Affecting Biotechnology 
As we turn to key patent activities affecting biotechnology, it is 
important to note that U.S. leadership in biotechnology has benefited 
historically from a strong intellectual property environment.  Policies 
ensuring effective and efficient operation of the U.S. patent system, fostering 
early-stage venture capital investment, and enhancing the effectiveness of 
technology transfer are likely to enhance the strength of the U.S. and the 
global biotechnology sector.48  However, some recent patent reform 
activities may have a negative impact on the ability of the U.S. to continue 
its leadership in biotechnology in a changing policy environment.  Some of 
the key reform proposals under discussion by government and industry 
groups include: 1) first-to-file patent system; 2) limits on filing of 
continuation patent applications; and 3) limits on availability of injunctive 
relief. 
First-to-File 
 With respect to a first-to-file system of patents, many hurdles and 
problems encountered by inventors in general could be minimized or 
eliminated.  The United States is currently the only country in the world that 
gives priority to the application that claims the earliest invention date i.e. 
                                                 
48 Hermans et al., supra note 39, at 266. 
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“first person to invent,” regardless of which application arrives first.  A first-
to-file system as opposed to “first person to invent” system would provide 
certainty in the patent application process by a clear metric of a filing date.  
First-to-file would eliminate costly interference proceedings used to 
determine priority of invention dates, and it would harmonize US patent 
practice with the rest of the world, especially with the European Patent 
Office and the Japan Patent Office.49     
However, a first-to-file patent system may not be the best for 
biotechnology or small inventors.  Because of their complexity, 
biotechnology inventions may take a long time to develop, and a race to the 
patent office under a first-to-file system would likely lead to patent 
applications that do not satisfy the requirements for enablement and written 
description.  Moreover, small inventors may lack the resources for expedited 
research and patent filings which would be necessary for success under a 
first-to-file system. 
Continuation Applications 
 In the case of Continuation Applications, it is a well-settled practice in 
U.S. patent law that patent applicants can file an unlimited number of 
continuation applications that claim the benefit of the filing date of the 
                                                 
49 Robert M. Seto, A Federal Judge’s View of the Most Important Changes in Patent Law in Half-A-
Century, 11 J. TECH. L. & POL’Y 141, 146 (2006). 
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original patent application.  Continuation practice is extremely important to 
the biotechnology and pharmaceutical industries because it allows patent 
applicants time to continue research and development efforts to improve 
their discoveries and refine their technologies for commercialization.  
Because  biotechnology companies typically file broad initial patent 
applications on a class of new drug products or therapeutics, which 
applications are subsequently refined and narrowed, continuation 
applications are the key to achieving the best patent coverage.   
  The United States Patent and Trademark Office last year proposed 
new rules that would restrict the use of continuations in patent prosecution.50 
Last year, SmithKline Beecham Corporation filed a lawsuit against the 
United States Patent and Trademark Office to enjoin it from enacting the 
proposed rules.51  This action by SmithKline was an historic challenge to 
rulemaking authority in an effort to protect the existing continuation 
practice.  I represented Elan Pharmaceuticals in an amicus filing supporting 
SmithKline.  As a result, we were successful in getting the United States 
District Court to permanently enjoined the United States Patent and 
Trademark Office from enacting the proposed changes to the continuation 
                                                 
50 Changes to Practice for Continued Examination Filings, Patent Applications Containing Patentably 
Indistinct Claims, and Examination of Claims in Patent Applications, 72 Fed. Reg. 46716 (proposed 
Aug. 21, 2007) (to be codified at 37 C.F.R. pt. 1.114 – pt. 1.78). 
51  Tafas v. Dudas, 541 F.Supp.2d 805 (E.D. Va. 2008). 
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practice.52  Preserving the practice of filing unlimited continuation 
applications will allow biotechnology and other science-based firms to 
develop and implement the best patent procurement strategies. 
Injunctive Relief 
 Turning to injunctive relief, the issuance of permanent injunctions by 
trial courts in the U.S. has been a practice which is consistent with the 
fundamental right to exclude others from making, using, offering for sale or 
selling a patented invention.  Injunctions were usually issued automatically 
once there had been a finding of infringement and validity.  Last year, the 
U.S. Supreme Court in the case of eBay v. MercExchange LLC53 decided 
that lower courts, in granting permanent injunctions to exclude others from 
making, using or selling a plaintiff’s patented product, must consider the 
well established four-factor test in determining whether injunctive relief 
should be granted.  Under the four-factor test, consideration should be given 
to: 1) whether the plaintiff suffered an irreparable injury; 2) whether the 
remedies available at law, such as monetary damages, are inadequate to 
compensate for that injury; 3) whether, in considering the balance of the 
hardships between the plaintiff and defendant, a remedy in equity is 
warranted; and 4) whether the public interest would be served by the 
                                                 
52  Id. at 817. 
53 126 S.Ct. 1837 (2006). 
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issuance of a permanent injunction.54  While the Court’s decision in eBay is 
consistent with the current patent statute which mandates courts to grant 
injunctions in accordance with the principles of equity, the Court’s ruling 
was more than likely influenced, in significant part, by changes in 
technology, new trends in patent cases, and a past practice of not granting 
injunctions where the patent holder is primarily using his patents for 
obtaining licenses, where the patented invention is but a small component of 
the infringing product or where the patent is for a business method.55  The 
Court’s decision brings patent cases in line with other equitable actions and 
causes biotechnology companies and other related technology companies to 
raise concerns related to strategy and planning for leveraging their patent 
portfolios.   
Other Key Patent Activities Affecting Biotechnology 
Notwithstanding the U.S. leadership role in sustaining a viable patent 
system, the reforms that I have discussed may lead some inventors and 
innovators to believe that a greater level of uncertainty does in fact exist in 
the patent practice.  Adding to this uncertainty is the totality of court 
decisions, congressional reform, United States Patent and Trademark Office 
rule changes, U.S. Federal Trade Commission (FTC) enforcement activities 
                                                 
54 Id. at 1839. 
55  Id. at 1842 (Kennedy, J. concurring). 
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and media related scrutiny.  Focusing specifically on court decisions, the 
U.S. Supreme Court has recently played more of an activist role in shaping 
the current state of patent law since the establishment of the Court of Appeal 
for the Federal Circuit in 1982.  According to a study by Professor John 
Duffy of George Washington University School of Law, the U.S. Supreme 
Court has traditionally heard one patent case every two years.  In the past 
three years the Court’s involvement has been enhanced to include reviewing 
three patent cases every two years.  The reason for this increased Supreme 
Court activity is not clear.  Could it be because of increasing frustrations 
with the decisions of the Circuit Court of Appeals for the Federal Circuit?  Is 
it over-aggressiveness of patent owners in obtaining and enforcing patent 
rights?  Is there a need to harmonize patent law with other legal 
jurisprudence?  Is it the huge impact that patents have on innovation, 
corporate valuation and overall global economy?  Is it lastly, the increased 
media attention focused on bad patents and evils of intellectual property?  
Some would argue that the preponderance of the recent U.S. Supreme Court 
cases has weakened the rights of patent owners by making it more difficult 
to obtain injunctions on the one hand and easier to challenge or invalidate 
patents on the other.   
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A good example of the weakening of patent rights by the US Supreme 
Court is the case of Merck KGaA v Integra Lifesciences I, LTD.56  Integra 
held patents directed to a class of compounds that Merck tested for use with 
angiogenesis inhibiters.  Integra filed a patent infringement action against 
Merck, alleging that the use of its patented compounds in preclinical testing 
constituted patent infringement.  The Court, in its decision, concluded that in 
certain circumstances drug companies can conduct preclinical research using 
patented compounds without risk of infringement.57  Given the decision in 
Merck v. Integra and other recent Supreme Court decisions related to the 
validity of patents, pundits and Court watchers contend that the Court may 
be improperly legislating from the bench for outcomes that ultimately 
diminish the rights of patent owners.58 
Issues to Watch – Final Thoughts 
 As I bring this discussion to a conclusion, I would like to share with 
you some final thoughts regarding issues to watch.  As we discussed, at the 
broadest level biotechnology is an industry that includes innovation and 
commercialization that are supported by patents.  The breadth of patent 
filings and the issuance of patents on more basic discoveries are on the rise.  
                                                 
56 545 U.S. 193 (2005). 
57 Id. at 208. 
58 See, e.g., Impact of Patent Law Changes on Biomedical Investment and Innovation, California 
Healthcare Institute (2008), 
http://www.chi.org/uploadedFiles/CHI%20Patent%20Law%20changes%20paper.pdf 
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This pattern, however, has created what some would characterize as a 
“Patent Thicket”59 in biotechnology.  That is, emerging from the 
overabundance of patent filings and associated activity is “a dense web of 
overlapping intellectual property rights”60 that requires those seeking to 
commercialize new technology to obtain licenses from multiple patentees.61  
Pharmaceutical companies typically grow a patent thicket seeking a wide 
range of chemical variants and analogs, methods of synthesizing the drug, 
chemical intermediates in this synthesis, different crystal forms, different 
finished dosage forms and various methods of use.62  Obtaining permission 
from various patent holders for use of patents can prove to be difficult 
particularly if the patent holder’s objective in creating the thicket is to block 
innovation by outsiders.   Because useful innovation in biotechnology 
requires multiple inventive steps and technologies, we could conceivably 
witness cumulative innovation with infringement on many patents which 
ultimately serves as a drag on innovation and commercialization.63  
 Another area which is emerging as a significant topic for 
consideration in patenting circles and is tangentially related to the “Patent 
                                                 
59 TAYLOR AND CAYFORD, supra note 38 
60 See Navigating the Patent Thicket: Cross Licenses, Patent Pools and Standard Setting, in 1 INNOVATION 
POLICY AND THE ECONOMY 119, 120 (Adam B. Jaffe, Josh Lerner & Scott Stern eds., 2001). 
61 Id.. 
62 See MICHAEL A. GOLLIN, DRIVING INNOVATION: INTELLECTUAL PROPERTY STRATEGIES FOR A DYNAMIC 
WORLD 168-69 (2008).  
63 Jaffe et al., supra note 60, at 121. 
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Thicket” phenomenon is compulsory licensing in both the U.S. and in 
Europe.  While compulsory licensing in the U.S. is not a creature of patent 
law, an example of where there is an attempted statutory direction for 
compulsory licensing is through the implementation of the Bayh-Dole Act.64  
This act permits compulsory patent licensing when a recipient of federal 
grants and contracts has not taken, or is not expected to take within a 
reasonable time, effective steps to achieve practical applications of the 
subject invention.  Attempts have also been made to carve out a compulsory 
licensing remedy judicially such as in the eBay case where the courts have 
utilized a public interest test in determining whether injunctive relief should 
be granted — the effect of which is compulsory licensing.  In the European 
Union, the issue of compulsory licensing is murky, notwithstanding the 
existence of the Doha Declaration which allows for compulsory licensing in 
developed countries for the manufacture of patented drugs.65   
     Lastly, proposed legislation for bio-generics or bio-similars66 should 
be carefully followed by the biotechnology industry.  There is no current 
regulatory pathway for bio-generic products in the United States, although 
the European Union has enacted some regulations.  Bio-generic and bio-
                                                 
64 Bayh-Dole Act, 35 U.S.C. §§ 200-212 (2008). 
65 World Trade Organization, Ministerial Declaration of 14 November 2001, WT/MIN(01)/DEC/1, 41 
I.L.M. 746 (2002) [hereinafter Doha Declaration]. 
66 Bio-similars refers to approved recombinant drugs (e.g. insulin, human growth hormone, interferons, 
erythropoietin) which are copied and marketed after the expiration of their patents. 
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similar regulations over the coming years will have a huge impact on the 
competitive landscape for biotechnology products.  
Conclusion 
 In conclusion, the global intellectual property system, since the days 
of the Venetians, has evolved from a system of sectarian interest and 
parochial politics to one which is open to ensuring innovation throughout the 
world.  More specifically, the international patent system “has entered a 
brave new scientific epoch”67 in which scientists, inventors, researchers, 
jurists and business persons are beginning to understand how best to treat the 
daunting array of discoveries emerging from biotechnology.68  With the U.S. 
patent system as the standard bearer and TRIPS as the global enforcer, 
innovation and the commercialization of biotechnology will not only be 
ensured, but it will also be guaranteed that life-saving medicines and other 
related products, which are a result of patented discoveries, will reach those 
in world who are most in need.  The global patent system as we know it is 
not a perfect system but it is one that holds promise for success and one that 
                                                 
67 Reichman and Dreyfuss, supra note 3, at 129. 
68 Id. 
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will allow us, as a world community, to heal, fuel and feed this planet we all 
share.69 
 Thank you for this opportunity to speak.  I am happy to respond to 
any questions that you may have at this time. 
 
                                                 
69 See A Vision For Innovation: Healing, Fueling and Feed the World, Address by the Honorable James C. 
Greenwood, President & CEO, Biotechnology Industry  Organization, BIO International Convention, 
San Diego, California (June 19, 2008) 
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